Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Lung cancer: a review of current therapeutic modalities.
Lung
October 1992
Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06510.
This article describes the current approach to the systematic management of both small cell and non-small cell lung cancer (NSCLC). The treatment of stages I, II, and IIIa NSCLC is surgical resection. Although adjuvant chemotherapy in stage I disease offers no survival benefit, the role of adjuvant chemotherapy in stage II and IIIa NSCLC remains controversial.
View Article and Find Full Text PDFCA 125 regression: a model for epithelial ovarian cancer response.
Am J Obstet Gynecol
August 1991
Department of Obstetrics and Gynecology, University of California, Irvine, Medical Center.
The rate of decline of CA 125 in effectively treated epithelial ovarian cancer is described by the exponential regression curve CA 125 = EXP [i - s (days after surgery)]. In this equation i, the y-axis intercept, measures initial tumor burden whereas s, the slope of the regression curve, is determined by the extent of cytoreductive surgery and the subsequent response to chemotherapy. Departure from the regression curve uniformly results in progressive disease.
View Article and Find Full Text PDFOvarian epithelial tumors of low malignant potential.
Surg Gynecol Obstet
August 1989
Department of Obstetrics and Gynecology, University of California, Irvine Medical Center, Orange.
Forty-one patients with epithelial ovarian tumors of low malignant potential are discussed. Twenty-three patients presented with Stage I, four with Stage II and 14 with Stage III disease. All patients with Stage I disease were solely treated surgically.
View Article and Find Full Text PDFHigh dose peptichemio in pretreated neuroblastoma.
Anticancer Res
December 1989
Giannina Gaslini Children's Hospital, Genova, Italy.
The aim of this study was to evaluate the antitumor effect and toxicity of a single course of Peptichemio at high dose (450 mg/sq m) given to children with neuroblastoma resistant to first line treatment or at relapse. A total of 28 children were treated. Seven children showed partial response, 4 minor response, 8 had stable disease, and in 8 the tumor progressed.
View Article and Find Full Text PDFNeoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients.
J Surg Oncol
April 1989
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Forty-one patients with marginally resectable stage III M0 non-small cell lung cancer (NSCLC) were entered into a study evaluating neoadjuvant cyclophosphamide, adriamycin, and cisplatin chemotherapy (CAP) followed by radiotherapy and subsequent resection. Postoperative radiotherapy and additional CAP were also administered. The objective disease regression rate prior to surgery was 72% (2 complete, 12 partial, and 7 minimal responses).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!